Open Access
Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
2
Center for Bio-Healthcare Materials, Bio-Convergence Materials R&D Division, Korea Institute of Ceramic Engineering and Technology, 202 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju 28160, Republic of Korea
|
Publication type: Journal Article
Publication date: 2023-08-09
PubMed ID:
37631316
Pharmaceutical Science
Abstract
Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Polymers
5 publications, 4.76%
|
|
|
Pharmaceutics
4 publications, 3.81%
|
|
|
International Journal of Biological Macromolecules
4 publications, 3.81%
|
|
|
Journal of Drug Delivery Science and Technology
4 publications, 3.81%
|
|
|
Gels
4 publications, 3.81%
|
|
|
ACS Nano
3 publications, 2.86%
|
|
|
Journal of Molecular Liquids
3 publications, 2.86%
|
|
|
Foods
2 publications, 1.9%
|
|
|
Stem Cell Research and Therapy
2 publications, 1.9%
|
|
|
Langmuir
2 publications, 1.9%
|
|
|
Macromolecular Materials and Engineering
2 publications, 1.9%
|
|
|
Molecular Pharmaceutics
2 publications, 1.9%
|
|
|
Frontiers in Bioengineering and Biotechnology
2 publications, 1.9%
|
|
|
ACS Sustainable Chemistry and Engineering
2 publications, 1.9%
|
|
|
International Journal of Pharmaceutics
1 publication, 0.95%
|
|
|
Agrochemicals
1 publication, 0.95%
|
|
|
Chemical Society Reviews
1 publication, 0.95%
|
|
|
Colloids and Surfaces B: Biointerfaces
1 publication, 0.95%
|
|
|
Journal of Macromolecular Science - Pure and Applied Chemistry
1 publication, 0.95%
|
|
|
Saudi Pharmaceutical Journal
1 publication, 0.95%
|
|
|
Scientific Reports
1 publication, 0.95%
|
|
|
BMC Biotechnology
1 publication, 0.95%
|
|
|
Pharmaceuticals
1 publication, 0.95%
|
|
|
Journal of Photochemistry and Photobiology A: Chemistry
1 publication, 0.95%
|
|
|
Journal of Biomedical Materials Research - Part B Applied Biomaterials
1 publication, 0.95%
|
|
|
Beilstein Journal of Nanotechnology
1 publication, 0.95%
|
|
|
Biochimica et Biophysica Acta - General Subjects
1 publication, 0.95%
|
|
|
Virtual and Physical Prototyping
1 publication, 0.95%
|
|
|
European Journal of Pharmaceutical Sciences
1 publication, 0.95%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
28 publications, 26.67%
|
|
|
MDPI
21 publications, 20%
|
|
|
American Chemical Society (ACS)
14 publications, 13.33%
|
|
|
Springer Nature
13 publications, 12.38%
|
|
|
Wiley
9 publications, 8.57%
|
|
|
Taylor & Francis
5 publications, 4.76%
|
|
|
Royal Society of Chemistry (RSC)
4 publications, 3.81%
|
|
|
AIP Publishing
2 publications, 1.9%
|
|
|
Frontiers Media S.A.
2 publications, 1.9%
|
|
|
King Saud University
1 publication, 0.95%
|
|
|
Research Square Platform LLC
1 publication, 0.95%
|
|
|
Beilstein-Institut
1 publication, 0.95%
|
|
|
Oxford University Press
1 publication, 0.95%
|
|
|
Tsinghua University Press
1 publication, 0.95%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.95%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.95%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
105
Total citations:
105
Citations from 2024:
102
(97.14%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Khaliq N. U. et al. Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy // Pharmaceutics. 2023. Vol. 15. No. 8. p. 2102.
GOST all authors (up to 50)
Copy
Khaliq N. U., Lee J., Kim S., Sung D., Kim H. Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy // Pharmaceutics. 2023. Vol. 15. No. 8. p. 2102.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3390/pharmaceutics15082102
UR - https://doi.org/10.3390/pharmaceutics15082102
TI - Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
T2 - Pharmaceutics
AU - Khaliq, Nisar Ul
AU - Lee, Juyeon
AU - Kim, Sangwoo
AU - Sung, Daekyung
AU - Kim, Hyungjun
PY - 2023
DA - 2023/08/09
PB - MDPI
SP - 2102
IS - 8
VL - 15
PMID - 37631316
SN - 1999-4923
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Khaliq,
author = {Nisar Ul Khaliq and Juyeon Lee and Sangwoo Kim and Daekyung Sung and Hyungjun Kim},
title = {Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
publisher = {MDPI},
month = {aug},
url = {https://doi.org/10.3390/pharmaceutics15082102},
number = {8},
pages = {2102},
doi = {10.3390/pharmaceutics15082102}
}
Cite this
MLA
Copy
Khaliq, Nisar Ul, et al. “Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy.” Pharmaceutics, vol. 15, no. 8, Aug. 2023, p. 2102. https://doi.org/10.3390/pharmaceutics15082102.